Alnylam Pharmaceuticals
ALNY
#1145
Rank
A$29.65 B
Marketcap
A$221.41
Share price
-2.98%
Change (1 day)
-67.41%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

ESG Reports

Thumbnail Alnylam Pharmaceuticals
 ESG Report 2025

ESG Report 2025

Language: English

View ESG Report
Thumbnail Alnylam Pharmaceuticals
 ESG Report 2024

ESG Report 2024

Language: English

View ESG Report